OTCM
GLAXF
Market cap101bUSD
Sep 17, Last price
24.56USD
1D
0.00%
1Q
-4.43%
Jan 2017
1.49%
Name
GSK plc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities span the entire lifecycle of healthcare products, encompassing research, development, manufacturing, and commercialization. Its broad portfolio includes pharmaceuticals, vaccines, over-the-counter medications, and a range of health-focused consumer products. The company operates through four primary divisions: Pharmaceuticals, Pharmaceutical Research & Development, Vaccines, and Consumer Healthcare. Within its pharmaceutical arm, GSK provides therapeutic solutions for a broad spectrum of conditions. These include ailments in respiratory health, HIV, immuno-inflammation, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital issues, metabolic diseases, bacterial infections, and dermatology. The consumer healthcare division delivers products across wellness, oral health, nutrition, and skin health categories. These are available in numerous formats, including nasal sprays, tablets, syrups, lozenges, gum and transdermal patches, caplets, infant syrup drops, liquid suspensions, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams, non-medicated patches, lip balms, gummies, and soft chews. GSK also maintains collaborative agreements with various organizations such as 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Furthermore, strategic partnerships are in place with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The firm, known as GlaxoSmithKline plc until its name change to GSK plc in May 2022, embodies centuries of innovation in healthcare.
Related entities
Subsidiaries (54)
14245563 CANADA INC.
BELLUS HEALTH INC.
BURROUGHS WELLCOME INTERNATIONAL LIMITED
CORIXA CORPORATION
ESKAYLAB LIMITED
GLAXO GROUP LIMITED
GLAXO OPERATIONS UK LIMITED
GLAXO WELLCOME PRODUCTION
GLAXO WELLCOME SA
GLAXO WELLCOME UK LIMITED
GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS KFT.
GLAXOSMITHKLINE CAPITAL INC.
GLAXOSMITHKLINE HOLDINGS LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
GLAXOSMITHKLINE LIMITED
GLAXOSMITHKLINE LLC
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
GLAXOSMITHKLINE SERVICES UNLIMITED
Key people
Independent Non-Executive Chairman of the Board · since 2019
Chief Financial Officer, Executive Director · since 2019
Roger G Connor
President - Vaccines · since 2018
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare · since 2016
Luke Miels
President - Global Pharmaceuticals · since 2017
Regis Simard
President - Pharmaceutical Supply Chain · since 2018
Deborah Waterhouse
Chief Executive Officer - ViiV Healthcare · since 2020
Diana Conrad
Senior Vice President - Human Resources · since 2019
James Ford
Senior Vice President, General Counsel · since 2018
Nick Hirons
Senior Vice President � Global Ethics and Compliance · since 2014
Sally Jackson
Senior Vice President - Global Communications and CEO Office · since 2019
Daniel E. Troy
Senior Vice President, General Counsel · since 2008
Chief Digital & Technology Officer · since 2017
Chief Scientific Officer, President - Research & Development, Executive Director · since 2018
Chief Financial Officer, Executive Director · since 2011
Patrick Vallance
President - Pharmaceuticals R&D, Executive Director · since 2017
Chief Executive Officer, Executive Director · since 2017
Senior Vice President - Human Resources · since 2008
Chief Strategy Officer · since 2008
Company Secretary · since 2011
Headquarters & legal address
79 NEW OXFORD STREET
LONDON, LND WC1A 1DG
GB
LONDON, LND WC1A 1DG
GB
Previous name
GLAXOSMITHKLINE PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||